<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">Lymphoproliferative diseases</z:e> that occur in immunocompromised patients are frequently associated with herpesviruses </plain></SENT>
<SENT sid="1" pm="."><plain>These patients often fare poorly after treatment with conventional chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>We reported previously that patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) responded to parenteral <z:chebi fb="1" ids="10110">azidothymidine</z:chebi> (<z:chebi fb="39" ids="10110">AZT</z:chebi>) and IFN-alpha </plain></SENT>
<SENT sid="3" pm="."><plain>We found that EBV-positive <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells derived from these patients cultured with <z:chebi fb="39" ids="10110">AZT</z:chebi> express CD95 and undergo <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="39" ids="10110">AZT</z:chebi>-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was caspase dependent and occurred despite Fas receptor blockade </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, EBV-negative <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were resistant to <z:chebi fb="39" ids="10110">AZT</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, as were EBV-positive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> that expressed high levels of bcl-2 </plain></SENT>
<SENT sid="6" pm="."><plain>Primary effusion <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PEL) cell lines infected with human herpesvirus type 8 required IFN-alpha to potentiate <z:chebi fb="39" ids="10110">AZT</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>IFN-alpha did not up-regulate CD95 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> or PEL but did induce expression of the <z:hpo ids='HP_0011420'>death</z:hpo> receptor ligand, CD95 ligand </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="39" ids="10110">AZT</z:chebi>-sensitive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> also accumulated significantly higher intracellular <z:chebi fb="39" ids="10110">AZT</z:chebi> monophosphate than did resistant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Our data demonstrated distinct apoptotic responses to <z:chebi fb="39" ids="10110">AZT</z:chebi> and IFN-alpha in herpesvirus-associated <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells that expressed low BCL-2 levels were sensitive to <z:chebi fb="39" ids="10110">AZT</z:chebi> alone; PEL cells required the addition of IFN-alpha to enhance <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and EBV-negative <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were insensitive to both agents </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="39" ids="10110">AZT</z:chebi>-sensitive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells transfected with BCL-2 became resistant </plain></SENT>
<SENT sid="12" pm="."><plain>Susceptibility to antivirus-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> may be exploited to improve the therapy of certain herpesvirus-associated <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>